Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a clinical trial registry record with no reported results; the study is active but not yet recruiting completion, precluding evidence of efficacy.
Meta-analysis of 3 RCTs and 8 observational studies shows apixaban and rivaroxaban associated with lower bleeding risk versus warfarin in dialysis patients with AF, but efficacy endpoints show substantial heterogeneity and RCT-only analysis lacked statistical significance; evidence is suggestive but requires dedicated large RCTs.